Showing results (1371-1380 of 11,281) with videos related to
Sort By:
Pageof 1,129
Pharmaceuticals (Basel, Switzerland)|October 29, 2025
Design of Hybrid Quinoline-Chalcone Compounds Against Leishmania amazonensis Based on Computational Techniques: 2D- and 3D-QSAR with Experimental ValidationMarcos Lorca, Gisela C Muscia, Jaime Mella, et al.Pharmaceuticals (Basel, Switzerland)|October 29, 2025
Acute and Subchronic Exposure to Hemp (Cannabis sativa L.) Leaf Oil: Impacts on Vital Organs in Sprague-Dawley RatsPutcharawipa Maneesai, Monchai Duangjinda, Chanon Labjit, et al.Pharmaceuticals (Basel, Switzerland)|October 29, 2025
Computational Investigation of the Potential Antileishmanial Mechanism of the Nitroindazole Derivative VATR131Omar Casanova-Alvarez, Niurka Mollineda-Diogo, Aliuska Morales-Helguera, et al.Pharmaceuticals (Basel, Switzerland)|October 29, 2025
Expression and Clinical Significance of Cytochrome 1B1 in Bone SarcomasBelal Al-Zu'bi, Fatemah Ofo Alshammari, Randa AlQaisi, et al.Pharmaceuticals (Basel, Switzerland)|October 29, 2025
Tissue-Specific Enhancement of Insulin Function and Restoration of Glucose-Stimulated Insulin Secretion by Croton guatemalensis Lotsy and Eryngium cymosum F. DelarocheFernanda Artemisa Espinoza-Hernández, Angelina Daniela Moreno-Vargas, Andrea Díaz-Villaseñor, et al.Pharmaceuticals (Basel, Switzerland)|October 29, 2025
Wound Healing: Molecular Mechanisms, Antimicrobial Peptides, and Emerging Technologies in Regenerative MedicineAna Paula de Araújo Boleti, Ana Cristina Jacobowski, Breno Emanuel Farias Frihling, et al.Pharmaceuticals (Basel, Switzerland)|October 29, 2025
An Efficacy- and In Vivo Exposure-Oriented Integrated Study to Investigate the Effective Components of Qishen GranuleYueting Li, Tengteng Wang, Chao Cheng, et al.Pharmaceuticals (Basel, Switzerland)|October 29, 2025
Mining Microbial Dark Matter: Advanced Cultivation Techniques for Bioactive Compound DiscoveryMinhui Ji, Bingda Ma, Jiayu Dong, et al.Pharmaceuticals (Basel, Switzerland)|October 29, 2025
Discovery of Personalized Treatment for Immuno-Metabolic Depression-Focus on 11beta Hydroxysteroid Dehydrogenase Type 2 (11betaHSD2) and Toll-like Receptor 4 (TLR4) Inhibition with EnoxoloneHarald MurckPharmaceuticals (Basel, Switzerland)|October 29, 2025
Immunomodulatory Activities of Emerging Rare Ginsenosides F1, Rg5, Rk1, Rh1, and Rg2: From Molecular Mechanisms to Therapeutic ApplicationsChang-Eui Hong, Su-Yun LyuPageof 1,129